0.00Open0.00Pre Close0 Volume0 Open Interest340.00Strike Price0.00Turnover61.88%IV-34.35%PremiumDec 20, 2024Expiry Date86.93Intrinsic Value100Multiplier20DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9903Delta0.0024Gamma2.91Leverage Ratio-0.0123Theta-0.0265Rho-2.88Eff Leverage0.0136Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet